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Defensins — small cationic antimicrobial pep-
tides — are recognized presently as an important com-
ponent of innate imm�nity that protects the host from 
invading microorganisms [�]. In the last years it has 
been established that apart from direct antimicrobial 
action defensins possess m�ltiple biological activities� 
in partic�lar� chemokine activity� and a n�mber of im-
m�nomod�latory activities as well [�� �].
Beta-defensins �hBDs� are peptides composed 
of 4��4� amino acid resid�es with characteristic 
cysteine pairing bonds ���� ��4� ��� [4]. Expression 
of beta-defensins is fo�nd predominantly in epidermis 
and epitheli�m lining different organs� in partic�lar� 
in respiratory and gastrointestinal tract — the largest 
s�rfaces of body contacting with antimicrobial agents. 
In respiratory tract the distrib�tion of hBDs is shown 
to be complementary — hBD-� is expressed in type-� 
alveolar epithelial cells� while expression of hBD-� is 
observed in bronch�s and bronchioli [�]. It is known 
also that hBD-� expression is constit�tive� while ex-
pression of hBD-� and hBD-� genes is ind�ced �pon 
the infl�ence of LPS and some cytokines [�� 7].
There is a n�mber of reports that have demonstra-
ted an importance of beta-defensin expression for an-
tibacterial protection of respiratory tract of mammals 
and man as well as the role of defensin malf�nction 
in different respiratory pathologies incl�ding cystic 
fibrosis� asthma� pne�monia [7�9].
Moreover� there are some data evidencing on pos-
sible implication of defensins� in partic�lar� hBD-�� 
in l�ng cancer [��]. The a�thors have eval�ated the 
ser�m hBD-� and hBD-� levels in two gro�ps of pa-
tients with l�ng cancer and pne�monia� and in healthy 
individ�als� and fo�nd significant elevation of hBD-� 
in blood ser�m of l�ng cancer patients compared to 
control [��]. The ser�m hBD-� level was also increased 
in l�ng cancer patients compared to healthy donors� 
b�t the difference was fo�nd to be insignificant. How-
ever� the data on the patterns of expression of defensin 
genes in h�man l�ng cancer cells are scarce� and the 
f�nctional role of hBDs expression in l�ng t�morigen-
esis remains largely �nknown.
In o�r earlier st�dies� we have fo�nd hBD-� �p-
reg�lation in cells of some h�man epithelial t�mors 
�cervical� v�lval� gastric� [�����]. The present pilot 
research was aimed on the st�dy of hBDs expression 
patterns in h�man l�ng t�mors.
In the st�dy� the samples of s�rgically resected 
h�man l�ng t�mors �sq�amo�s cell carcinoma �SCC�� 
n = ��; adenocarcinoma �AC�� n = ��� paired with condi-
tionally normal tiss�e samples were st�died. The tiss�e 
samples were obtained d�ring the s�rgical treatment 
of patients with l�ng cancer c�red in the Thoracic De-
partment� National Cancer Instit�te �Kyiv� Ukraine�. The 
patients did not receive chemo- or radiotherapy prior to 
the s�rgery. All patients provided an informed written 
consent to perform the st�dy� and the present research 
was approved by Ethic Committee of the Instit�te. Im-
mediately after s�rgical removal� tiss�e samples were 
frozen in liq�id nitrogen and stored at �7� °C �ntil �se. 
The clinico-pathological characteristics of l�ng cancer 
patients and t�mors are presented in Table �.
Total RNA was isolated from tiss�e samples by the 
method of Chromzynski and Sacchi [�4]. RNA con-
centration was eval�ated at ��� nm �sing Beckman 
DU-�B spectrophotometer� its p�rity — by OD relation 
at ��� nm and ��� nm� its q�ality — by electrophoresis 
in �% agarose gel containing ��% formaldehyde. For 
detection of expression of hBD-�� hBD-�� hBD-4 in 
tiss�e samples� semiq�antitive RT-PCR analysis was 
performed �sing the set of specific primers �primer 
seq�ences and conditions of RT-PCR are presented 
in Table ��. The expression level of beta-actine served 
as the control. The prod�cts of RT-PCR were ro�tinely 
analyzed by electrophoresis in agarose gel.
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The content of hBD-� in blood ser�m of the patients 
with blood cancer was analyzed by imm�noenzyme 
method with the �se of beta-defensin-� �h�man� ELISA 
kit �Phoenix Pharmace�ticals� Inc.� USA�.
Table 1. Expression of hBDs mRNA in human lung tumors and healthy 
lung tissue samples 
Case TNM
Differen-
tiation 
grade
Expression level Content of 
hBD-2 in blood 
serum (pg/ml)
hBD-1 hBD-2 hBD-4
N T N T N T
Squamous cell carcinoma
1 T1N0M0 LD + + ++ +++ + + 520
2 T2N1M0 LD ++ + ++ +++ +++ +++ 320
3 T2N0M0 LD ++ +++ ++ ++ + + 360
4 T2N0M0 LD ++ +++ ++ +++ + + 30
5 T2N0M0 LD + ++ + +++ + +++ 0
6 T2N1M0 LD ++ ++ ++ + ++ +++ 0
7 T2N2M0 LD + + +++ ++ + - 1200
8 T2N1M0 MD ++ +++ ++ +++ + ++ NA
9 T2N1M0 MD +++ +++ + + + ++ NA
10 T3N0M0 MD + ++ – ++ + + NA
Adenocarcinoma
1 T2N1M0 MD + – ++ ++ +++ + NA
2 T2N1M0 MD ++ + – ++ + + 800
3 T2N1M0 MD ++ +++ ++ ++ + +++ 60
4 T2N1M0 MD + ++ – + + +++ 120
5 T2N1M0 Mixed 
type
++ +++ ++ ++ ++ ++ 40
6 T2N2M0 MD + ++ + ++ + + 120
7 T2N2M0 MD + ++ - +++ + + 0
8 T3N0M0 MD ++ + ++ +++ +++ + 840
9 T1N0M0 HD ++ + ++ + ++ ++ 640
10 T1NXMX HD – +++ ++ ++ ++ ++ 50
Notes: N — normal tissue; T – tumor tissue; differentiation grade: LD — low-
differentiated; MD — moderately-differentiated; HD – highly-differentiated; 
SCC —; AC –; “+, ++, +++” — low, moderate, high expression levels respectively; 
“–” — expression is non-detectable; NA – blood serum was not available.
Table 2. Primers for genes of interest used in the study
Gene Primer Conditions of RT-PCR
hBD-1 Forward -5�-tgttgcctgccagtcgccatgag
Reverse 5�-tcacttgcagcacttggccttccc
35 cycles (67 °С, 10 s; 
72 °С, 10 s)
hBD-2 Forward -5�-gaagctcccagccatcagcc  
Reverse -5�-gtcgcacgtctctgatgaggga 
35 cycles (59 °С, 10 s; 
72 °С, 10 s)
hBD-4 Forward -5�-gaagctcccagccatcagcc
Reverse 5�-gtcgcacgtctctgatgaggga
35 cycles (65 °С, 10 s; 
72 °С, 10 s)
Beta-
actine
Forward -5�-ctggaacggtgaaggtgaca
Reverse 5�-aagggacttcttgtaacaatgca
35 cycles (59 °С, 10 s; 
72 °С, 10 s)
With the �se of RT-PCR analysis it has been 
revealed that in total� ��% of st�died l�ng t�mor 
samples are characterized by overexpression of one 
of three st�died beta-defensin genes �hBD-�� hBD-� 
or hBD-4� compared to paired control tiss�e speci-
mens �see Table �; Fig�re�. For hBD-� mRNA� down-
reg�lation was detected in � of �� cases of SCC and 
in 4 cases of AC� while its �p-reg�lation — in � cases 
of SCC and � cases of AC. hBD-� was �p-reg�lated 
in ��% of SCC cases and in ��% of AC. Expression of 
hBD-4 was fo�nd to be a more stable para meter — its 
�p-reg�lation was detected only in 4 SCC cases and 
in � AC cases� while in �� of �� cases st�died in the 
present research the level of hBD-4 expression was 
eq�al in t�mor tiss�e sample and its paired condition-
ally normal specimen.
We have to state that the low n�mber of st�died 
cases and heterogeneity of hBDs expression do not al-
low �s to make partic�lar concl�sions on the pec�liarity 
of defensin expression in l�ng t�mors in dependence 
on the stage of the disease� differentiation grade� 
lymph node stat�s etc. In a small cohort of st�died l�ng 
cancer patients� no correlation between mentioned 
parameters was fo�nd. Also� the level of expression 
of hBD-� mRNA did not correlate with the content of 
hBD-� peptide in blood ser�m of the patients with l�ng 
cancer �Table�. However� s�mmarizing the obtained 
data� one may note that hBD-� and hBD-� expression 
is often �p-reg�lated in t�mor l�ng tiss�es. 
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figure. Semiq�antative RT-PCR analysis of expression of mRNA 
for hBD-�� hBD-� and hBD-4 in h�man l�ng sq�amo�s cell 
carcinomas �SCC� and adenocarcinomas �AC�. Expression of 
beta-actine served as internal control. Molec�lar weight markers 
�Fermentas  CeneR�ler � kb DNA Ladder  for hBD-4; Fermentas 
CeneR�ler �� bp DNA Ladder  for hBD-�� hBD-�� and beta actine� 
are shown. T � t�mor tiss�e; N � normal tiss�e
Expression patterns of beta-defensin genes in 
h�man t�mors are in spite of interest of few research 
gro�ps incl�ding o�r laboratory. Up-to-date there are 
reports showing that the t�mors of oral cavity� colon 
and stomach are characterized by elevated expression 
of some alpha- or beta-defensins [��� ��� ��]. 
There are also some st�dies where cancer-related 
down-reg�lation of defensin genes has been revealed: 
it was reported that in prostate and renal cancers 
defensin expression is down-reg�lated [�7]. It was 
demonstrated recently [��] that expression of h�man 
beta-defensin-� is down-reg�lated in prostate cancer� 
and the a�thors proposed that hBD-� may play a role 
of t�mor s�ppressor gene in prostate cancer cells. To 
test s�ch hypothesis� the a�thors have performed the 
cloning and ectopic expression of hBD-� in prostate 
cancer cells of different lines� and demonstrated that 
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hBD-� prod�ction by these cells led to their growth 
s�ppression and death [��]. 
However� in l�ng t�mors the patterns of hBD-� 
expression are different from these in prostate and 
renal cancers� and moderate down-reg�lation of 
hBD-� was observed only in � of �� st�died cases� 
while �p-reg�lation of hBD-� and hBD-� is a freq�ent 
event in both SCC and AC. These data are in accor-
dance with the data of Arim�ra et al. [��] who fo�nd 
significantly elevated concentrations of hBD-� and 
high concentrations of hBD-� in blood ser�m of l�ng 
cancer patients compared to these of patients with 
pne�monia and healthy donors. Taking into acco�nt 
the possible chemokine activities of beta-defensin-� 
and its ability to attract immat�re dendritic cells [�� 
�9]� one may hypothesize that �p-reg�lation of hBD-� 
in t�mor cells may res�lt in the beneficial effect to 
the host; however� the prognostic val�e of this index 
has not been st�died yet� and follow-�p data for l�ng 
cancer patients and monitoring of hBDs expression 
will be �sef�l to answer these q�estions. 
In concl�sion� o�r pilot investigation has revealed 
that in the st�died cohort the large majority of l�ng 
t�mors is characterized by �p-reg�lation of hBD-�� 
hBD-� or rarely - of hBD-4 mRNAs. Overexpression of 
hBD-� seems not be related to differentiation grade of 
the t�mor and its histological type� as well this param-
eter does not infl�ence the content of hBD-� peptide 
in blood ser�m of l�ng cancer patients. 
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Экспрессия мрнк бета-дефенсинов-1, 2, 4 в ткани 
опухоли легкого человека: пилотное исследование
Цель: проанализировать особенности экспрессии мРНК бета-дефенсинов-1, 2, 4 (hBDs) в ткани опухоли легкого человека. 
Материалы и методы: с помощью метода полуколичественного RT-PCR-анализа изучали уровень экспрессии мРНК 
hBD-1, 2, 4 в образцах ткани хирургически удаленных опухолей легкого человека (плоскоклеточный рак — ПКР, n = 10; 
аденокарцинома — AК, n = 10) по сравнению с образцами условно-нормальной ткани легкого тех же пациентов. Результаты: 
в ряде исследованных образцов опухолей легкого выявлена повышенная экспрессия мРНК hBD-1 (50% ПКР и 60% AК), 
hBD-2 (60% ПКР и 50% АК) или hBD-4 (40% ПКР и 20% AК). Зависимости между уровнем экспрессии бета-дефенсинов 
и гистологическим типом опухоли, стадией заболевания и содержанием пептида hBD-2 в сыворотке крови больных не 
установлено. Выводы: в ткани опухоли легкого человека часто активирована экспрессия hBD-1 и hBD-2. 
Ключевые слова: бета-дефенсины человека, опухоль легкого, экспрессия.
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